Enveric Biosciences, Inc. (ENVB)
Nasdaq · Healthcare · Biotechnology
$1.51+2.03%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $6.8M
- 52-week range
- $1.17 – $13.25
- 52-week change
- −82.28%
- EPS (trailing)
- −$13.01
Fiscal year to Dec 2025
- Net income
- $12.1M
- Diluted EPS
- −$36.24
From the company’s annual report on SEC EDGAR.
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 5 employees · enveric.com